Enzymatic Therapy, Green Bay, WI, has re-acquired the distribution rights for Remifemin, a leading OB/GYN-recommended, non-prescription menopausal therapy. The company was first to handle the brand’s distribution from 1995 to 2000. Then, Remifemin distribution went to GlaxoSmithKline Consumer Healthcare as the product entered mass markets. Now with Enzymatic Therapy’s recent growth and distribution acquisitions for Alluna, SneezEze and Renouvelle, the company said the timing was right for it to reacquire Remifemin. The transaction became effective June 20th when rights for the product were transferred. Enzymatic Therapy has partnered with Shaper & Brummer, GmbH & Co. KG, the German manufacturer of Remifemin, to increase product distribution and market share. The company will also be implementing practitioner and consumer education programs.